Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Faghfuri, Elnaz; Faramarzi, Mohammad Ali; Nikfar, Shekoufeh; Abdollahi, Mohammad
• Is Part Of: Expert review of anticancer therapy. Volume 15:Issue 9(2015)
• Page Start: 981
• Page End: 993
• Publication Date: 2015-09
• Subjects: Cancer -- Treatment -- Periodicals; 616.99406
• Languages: English
• ISSNs: 1473-7140

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Malignant melanoma is an important issue in oncology due to its high incidence, high mortality, and resistance to systemic therapy; however, targeted immunotherapy has noticeably improved the survival rates of melanoma patients. Promising targeted immunotherapies for malignant melanoma include the blockade of immune checkpoints with antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and the programmed cell death protein 1 pathway. The US FDA-approved antibody ipilimumab targets cytotoxic T lymphocyte-associated antigen 4; however, it was limited by toxicity and a low response. Nivolumab and pembrolizumab (formerly lambrolizumab), the two FDA-approved anti-programmed death-1 monoclonal antibodies, show highly durable response rates and long-term safety, validating the importance of the programmed cell death protein 1 pathway blockade for treatment of malignant melanoma.</p> </abstract>